Compare Costco Wholesale Corporation (COST) vs Incyte Corporation (INCY) Price & Performance

Costco (COST) trades at $947.92, up 0.6% on the day, near its pivot point of $947 with strong analyst consensus. The stock shows bullish moving averages but overbought RSI signals. Recent March sales surged 11.3% year-over-year to $28.41 billion (Costco report, April 8, 2026), while Q2 2026 EPS beat expectations. Valuation remains elevated with a P/E of 45.66, supported by robust membership fee growth and expansion.

Outlook is positive given consistent revenue growth and high renewal rates post-fee hike, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $1,100 implies ~16% upside, with institutional buying underscoring confidence. Key catalysts are Q3 2026 earnings and sustained comp sales momentum.

Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.

The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.